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Abstract
Aims: Invasion and metastasis are major reasons for pancreatic cancer death and identifying signaling molecules that are
specifically used in tumor invasion is of great significance. The purpose of this study was to elucidate the role of GEP100 in
pancreatic cancer cell invasion and metastasis and the corresponding molecular mechanism.
Methods: Stable cell lines with GEP100 knocked-down were established by transfecting GEP100 shRNA vector into
PaTu8988 cells and selected by puromycin. qRT-PCR and Western blot were performed to detect gene expression. Matrigel-
invasion assay was used to detect cancer cell invasion in vitro. Liver metastasis in vivo was determined by splenic injection of
indicated cell lines followed by spleen resection. Immunofluorescence study was used to detect the intracellular localization
of E-cadherin.
Results: We found that the expression level of GEP100 protein was closely related to the invasive ability of a panel of 6
different human pancreatic cancer cell lines. Down-regulation of GEP100 in PaTu8988 cells significantly decreased invasive
activity by Matrigel invasion assay, without affecting migration, invasion and viability. The inhibited invasive activity was
rescued by over-expression of GEP100 cDNA. In vivo study showed that liver metastasis was significantly decreased in the
PaTu8988 cells with GEP100 stably knocked-down. In addition, an epithelial-like morphological change, mimicking
a mesenchymal to epithelial transition (MET) was induced by GEP100 down-regulation. The expression of E-cadherin protein
was increased 2–3 folds accompanied by its redistribution to the cell-cell contacts, while no obvious changes were observed
for E-cadherin mRNA. Unexpectedly, the mRNA of Slug was increased by GEP100 knock-down.
Conclusion: These findings provided important evidence that GEP100 plays a significant role in pancreatic cancer invasion
through regulating the expression of E-cadherin and the process of MET, indicating the possibility of it becoming a potential
therapeutic target against pancreatic cancer.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer death
in the United States [1]. Recent data estimated that 43,140 new
cases were diagnosed, with approximately 36,800 associated
deaths in 2010 [2]. Pancreatic cancer is often diagnosed at the
advanced stages with local invasion and remote metastasis,
making surgical resection difficult and less effective [3]. Thus,
an enormous amount of effort has been made to try to inhibit
the invasive activities of carcinoma cells. For the development of
therapeutics, it is of great significance to identify the signaling
molecules that are specifically used in tumor invasion [4,5,6].
Guanine nucleotide-exchange protein 100, GEP100 (also called
BRAG2) was identified as one of the guanine nucleotide exchange
factors (GEF) that preferentially accelerated guanosine 5-[c-
thio]triphosphate (GTPcS) binding for Arf6 and responsible for
its following activation [7]. It has been reported that GEP100 was
involved in various biological processes including cell surface
receptor expression, cell-cell fusion, adhesion, phagocytosis,
apoptosis and angiogenesis [8–15]. Recent studies showed that
GEP100 played an important role in tumor invasion. GEP100
links epidermal growth factor receptor signaling to Arf6 activation
to induce breast cancer and lung cancer invasion [16,17]. At
present, the function of GEP100 in other cancers, including
pancreatic cancer, remains unknown.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37854A process called epithelial to mesenchymal transition (EMT)
often occurs during carcinoma progression. During this process,
the epithelial cells overcome the physical constraints imposed on
them by intracellular junctions and obtain the mesenchymal
phenotype and enhanced motility [18]. E-cadherin is a trans-
membrane protein localized at the adherens junctions of the
basolateral surface and plays an important role in epithelial
morphology maintenance. Loss of E-cadherin expression and/or
function is a well-recognized marker of EMT and promotes
pancreatic cancer cell progression and invasion, relating to the
poor prognosis of pancreatic cancer [19–23]. To date, the effect of
GEP100 on EMT is rarely studied.
Therefore, in this study, we investigated the function of GEP100
in the processes of pancreatic cancer cell invasion, metastasis and
EMT. We analyzed GEP100 expression in different cell lines and
found that the GEP100 expression level was closely related to cell
invasive abilities. Matrigel invasion assay in vitro and liver
metastasis experiment in vivo both revealed that down-regulation
of GEP100 inhibited invasion and metastasis significantly. The
expression of E-cadherin was up-regulated by GEP100 knock-
down. Our findings will help further revealing molecular
mechanisms used in the pancreatic cancer invasion and metastasis
processes.
Materials and Methods
Cell Culture and Antibodies
Human pancreatic cancer cell lines BxPC-3, CFPAC-1,
SW1990, AsPC-1, Panc-1 and PaTu8988 were all obtained from
Chinese Academy of Sciences Cell Bank (Shanghai, China) and
cultured in RPMI-1640 (Gibco) containing 10% fetal bovine
serum without antibiotics in a 5% CO2 incubator at 37uC.
Primary antibodies for Arf6, vimentin, b-actin were purchased
from Santa Cruz Biotechnology. Antibodies for GEP100 and E-
cadherin C36 were from Sigma and BD Biosciences respectively.
All secondary antibodies were from Boster Technology (Wuhan,
China).
Plasmids and Transfection
The pEGFP-GEP100 plasmid encoding the full length of
GEP100 cDNA and pSuper-retro-puro-GEP100 plasmid encod-
ing GEP100 shRNA were kind gifts from professor Sabe Hisataka
(Hokkaido University, Japan). For shRNA-mediated GEP100
suppression, 8610
5 of PaTu8988 cells were transfected with 3 mg
of psuper-retro-puro-GEP100 or a plasmid encoding an irrelevant
sequence using Lipofectamine 2000 (Invitrogen) for 48 hours. The
transfected cells were selected with 1 mg/ml puromycin (Invitro-
gen) and pools of selected cells were subjected to in virto
experiments including invasion, wound healing, adhesion and
viability assays. For the generation of stable cell lines, the
transfected cells were selected with 1 mg/ml puromycin and pools
of selected cells were serially diluted in a selection medium.
Approximately 20 clones were isolated and tested with Western
blot. The clone displaying the highest degree of suppression was
used for in vivo experiments.
Viability, Adhesion, Wound Healing and Matrigel Invasion
Assays
Cell viabilities were measured with a MTT colorimetric assay
kit (Promega) according to the manufacturer’s instructions.
For the adhesion assay, a 35 mm culture dish was coated with
10 mg/ml collagen I (Sigma-aldrich) and then 1610
5 cells were
seeded. 1 hour later, the dish was washed with PBS gently for 3
times. The number of cells adhered to the dish was counted.
For the wound healing assay, 1610
6 cells were seeded into
a 35 mm culture dish and allowed to form a monolayer. A wound
was made by scratching the monolayer with a 100 ml pipette tip.
The cells were cultivated till the wound was covered.
The Matrigel invasion assay was performed using a transwell
coated with 25 mg Matrigel (Sigma). 1610
5 cells in RPMI-1640
with 1% phosphate buffer saline (PBS) were seeded onto the upper
well. As a chemoattractant, RPMI-1640 with 10% FBS was added
into the lower compartment. After incubation for 24 hours, cells
were fixed in methanol for 15 min and stained with 1% crystal
violet (Sangon, China) for 10 min. The cells on the upper surface
of the filter were wiped off with a cotton swab and the number of
cells that migrated out to the lower surface of the membranes was
counted in 10 randomly selected fields.
RT-PCR Analysis
Total RNA was isolated from cultured cells by Trizol
(Invitrogen) and reverse-transcribed by M-MLV Reverse Tran-
scriptase (Promega) using oligo dT primers at 42uC for 60 min.
cDNAs were then subjected to 35 cycles of PCR amplification.
Primers used were listed below: GEP100, forward primer (59-
GCCTTTAGCAACGATGTCATC-39) and reverse primer (59-
CACATGGTCCTCATTGGTCTT-39); Arf6, forward primer
(59-ATGGGGAAGGTGCTATCCAAAATC-39) and reverse
primer (59-GCAGTCCACTACGAAGATGAGACC-39); E-cad-
herin, forward primer (59-TCCCATCAGCTGCCCAGAAA-39)
and reverse primer (59-TGACTCCTGTGTTCCTGTTA-39);
Vimentin, forward primer (59-GACAATGCGTCTCTGG-
CACGTCTT-39) and reverse primer (59-
TCTTCTGCCTCCTGCAGGTTCTT-39); Slug, forward prim-
er (59-AGATGCATATTCGGACCCAC-39) and reverse primer
(59-CCTCATGTTTGTGCAGGAGA-39); Twist, forward primer
(59-CACTGAAAGGAAAGGCATCA-39) and reverse primer (59-
GGCCAGTTTGATCCCAGTAT-39); ZEB1, forward primer
(59-AGCAGTGAAAGAGAAGGGAATGC-39) and reverse prim-
er (59-GGTCCTCTTCAGGTGCCTCAG-39); Snail, forward
primer (59-TTCTTCTGCGCTACTGCTGCG-39) and reverse
primer (59-GGGCAGGTATGGAGAGGAAGA-39). The primers
used for b-actin were purchased from Sangon, China.
Western Blot Analysis
Cells were lysed in RIPA lysis buffer (150 mM NaCl, 20 mM
Tris-HCl pH7.4, 5 mM EDTA, 1% NP-40, 1% Na-deoxycholate,
0.1% SDS, 1 mM PMSF, 20 mg/ml Leupeptin, 20 mg/ml
Aprotini, 3 mg/ml Pepstatin A) and the protein concentration
was determined using the BCA kit (Keygen, China). Total proteins
were fractionated using SDS-PAGE and transferred onto a nitro-
cellulose membrane. The membranes were blocked in 5% BSA in
TBST buffer containing 0.1% Tween 20 and then incubated with
indicated primary antibodies overnight at 4uC. HRP-conjugated
secondary antibodies were incubated at room temperature (RT)
for 1 hour and detected using the enhanced chemiluminesence
detection system (Amersham Pharmacia Biotech).
Immunofluorescence Study
The transfected PaTu8988 cells were washed with warm PBS
once and immediately fixed with cold methanol at 220uC for
6 min. The sample was allowed to dry at RT for 30 min and
blocked with 2% BSA in PBS for 30 min. The endogenous E-
cadherin was recognized with an anti-E-cadherin monoclonal
antibody for 1 hour at RT. After 5 washes with 0.5% BSA-PBS,
a FITC-labeled anti-mouse secondary antibody (Boster, China)
was added and incubated for 30 min at RT. Then the cells were
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glycerol in PBS and observed under a fluorescence microscope.
In vivo Metastasis Assay
A liver metastasis assay was performed as described previously
[24,25] with modifications. Briefly, Balb/c nude mice (5–6 weeks)
were divided into 3 groups with 12 for each: a control group
receiving the PaTu8988 cells, a scramble group receiving the cells
knocked-down with sramble shRNA and an experimental group
receiving the cells with GEP100 stably knocked-down. Mice were
anaesthetized with chloral hydrate. The abdominal cavity was
exposed and 5610
6 indicated cells in 0.1 ml PBS were injected
into the spleen tissue through a 27-gauge needle. The injection site
was pressed slightly with saline cotton for 5 min followed by the
ligation of the left gastric artery and splenic artery. Then the
spleen was resected. 4 weeks later, the liver was surgically removed
and fixed with 10% formalin overnight. The liver was cut into
2 mm slices and 5 sections from approximately the same position
for each liver were estimated under a microscope. The protocols
used for all animal experiments in this study were approved by the
Animal Research Committee of Zhejiang University.
Statistical Analysis
The experiments and assays were performed at least three times.
Statistical significance was assumed if P#0.05 by T-test.
Results
Correlation between GEP100 Expression and Pancreatic
Cancer Cell Invasive Ability
The invasive ability of a panel of 6 different human pancreatic
cancer cell lines was examined by the Matrigel invasion assay as
shown in Fig. 1A. The cell lines in this group were derived from
both the primary (BxPC3, Panc-1, and SW1990) and metastatic
(AsPC-1, CFPAC-1, and Patu8988) sites [26,27]. These cell lines
showed a continuum of different invasive abilities. The AsPc-1 and
PaTu8988 cells showed the highest invasive abilities, followed by
the SW1990, CFPAC-1 and Panc-1 cells. The BxPC-3 cell was the
weakest one. The expression level of GEP100 protein was closely
correlated with the invasive ability of this panel of cell lines, with
the AsPc-1 and PaTu8988 cells showing the strongest expression,
followed by the SW1990, CFPAC-1 and Panc-1 cells, while hardly
detected in the BxPC-3 cell line. No obvious relationship between
the expression of the Arf6 protein and invasive ability was
detected. We also determined the expression levels for the proteins
associated with epithelial (E-cadherin) or mesenchymal (Vimentin)
phenotype. E-cadherin expression could easily be detected in the
low-invasive cell lines, but only a very weak expression was
detected in the highly-invasive cell lines. Vimentin was expressed
in the highly-invasive cell line (Fig. 1B).
The expression of GEP100 mRNA could be detected in all the
6 cell lines and no obvious correlation with the invasive ability was
found. This was the same for Arf6 and vimentin mRNA. E-
cadherin mRNA level showed a close association with invasive
ability of different cell line (Fig. 1C).
Down-regulation of GEP100 Decreased the Invasive
Ability of Pancreatic Cancer Cells
To evaluate whether GEP100 contributes to cell invasion, we
chose the highly invasive PaTu8988 cells and down-regulated the
GEP100 expression with shRNA. More than 80% inhibition of
GEP100 protein synthesis was confirmed by Western blot in two
clones (Fig. 2A). Clone 1# was chosen for the invasion assay. The
Matrigel invasion assay showed that GEP100 knock-down de-
creased the number of cells penetrating through Matrigel to about
35% compared with the control group (Fig. 2B). Re-expression of
GEP100 restored the ability of invasion to about 60%. Migratory
activity was evaluated by the wound healing assay and wound
healing time periods of three groups were shown. GEP100 knock-
down only slightly inhibited the migration (Fig. 2C) with no
statistical significance. On the other hand, GEP100 knock-down
did not inhibit cell adhesion onto collagen (Fig. 2D). Under the
above conditions, cell viability was not affected (Fig. 2E).
Down-regulation of GEP100 Decreased Liver Metastasis
of Pancreatic Cancer Cells in Balb/c Nude Mice
Next, we examined whether knock-down of GEP100 blocks
liver metastasis of tumor cells in mice. We injected PaTu8988 or
PaTu8988/scramble shRNA or PaTu8988/GEP100 shRNA cells
into the spleens of Balb/c nude mice. Twelve mice from each
group were sacrificed after 4 weeks post injection. For the control
and scramble shRNA-injected groups, the liver became small and
rough, with whitened areas seen on the surface. For the GEP100
shRNA-injected group, small spots were also found at the liver
surface. Hepatic metastasis showing poorly differentiated nests of
cells was confirmed microscopically in 9 of 10 mice (90%) in the
control group and 10 of 12 mice (83%) in the sramble group, while
only 4 of 11 mice (36%) was found in the experimental group
(Fig. 3). A significant inhibitory effect on liver metastasis was
observed (P#0.05). The numbers of metastatic nodules were
calculated and averaged. Comparing with the control and the
scramble groups, GEP100 down-regulation decreased the meta-
static nodules significantly (P#0.05).
E-cadherin Expression was Up-regulated and
Redistributed to the Cell-cell Contact by GEP100 Down-
regulation
Finally, we investigated the possible mechanisms involved in the
invasion inhibition of pancreatic cancer cells by GEP100 down-
regulation. We found that down-regulation of GEP100 caused
a morphological change of PaTu8988 cells from mesenchymal
type to epithelial-like (Fig. 4A). And correspondingly, the
expression of E-cadherin protein, which is an epithelial marker,
was increased about 3-fold compared with the control group
(Fig. 4B). The expression of E-cadherin mRNA was also
examined, but no significant changes could be detected (Fig. 4C).
Next, we further determined the intracellular localization of E-
cadherin protein. Immunofluorescence study showed that in
GEP100 knocked-down cells, E-cadherin was concentrated at
the cell-cell contact (Fig. 4D). Although no significant change was
found at the mRNA level of E-cadherin, we still examined the
expression of several main transcription factors for E-cadherin.
Interestingly, an increase of Slug was found in the GEP100
knocked-down cells, while there was no change for Twist, ZEB1,
Snail (Fig. 4C).
Discussion
The current results demonstrated for the first time that GEP100
plays a pivotal role in pancreatic cancer cell invasion. Down-
regulation of GEP100 significantly inhibited the invasive abilities
of pancreatic cancer cells possibly through the up-regulation of the
expression of E-cadherin and restoration of the epithelial
phenotype. GEP100 might be a potential molecular target in
pancreatic cancer gene therapy.
In this study, first, we demonstrated that GEP100 was expressed
in the pancreatic cancer cells. GEP100 belongs to the BRAG
GEP100 in Pancreatic Cancer Invasion
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BRAG2/IQsec1/GEP100, and BRAG2/IQsec3/synArfGEF
[28]. The expression of BARG2/GEP100 is ubiquitous [7].
Within the panel of 6 pancreatic cancer cell lines we used, BxPC-
3, SW1990 were derived from primary tumors and Panc-1 was
derived from invasive intraductal extension of primary tumor,
while the other 3 were all derived from metastatic sites [26,27].
AsPc-1 and PaTu8988 showed the strongest expression of
GEP100, followed by SW1990, CFPAC-1 and Panc-1, while the
primary tumor of BxPC-3 cells showed the weakest. The
expression of GEP100 protein is closely related to the invasive
ability of each cell line, suggesting that GEP100 might be involved
in pancreatic cancer cell invasion.
We further found that GEP100 down-regulation with shRNA
significantly inhibited the Matrigel invasion ability of PaTu8988
cells, but had no effect on the cell viability, migration and
adhesion, indicating that GEP100 is particularly responsible for
the invasive ability of cells. In vivo experiment also showed that
GEP100 knock-down significantly inhibited the liver metastasis of
pancreatic cancer cells in Balb/c nude mice. This result was in line
with previous data demonstrating that in breast cancer cells
GEP100 was highly expressed in the invasive ones and that
GEP100 down-regulation inhibited cell invasion and lung
metastasis [16,17]. These results indicated that GEP100 is not
only a target for breast cancer, it might be a general mechanism
used by other cancer types.
Several other biological functions for GEP100 have been
reported. In HeLa cells, GEP100 regulated cell adhesion through
controlling endocytosis and recycling of integrin b [9]. In a liver
carcinoma cell line HepG2, GEP100 directly interacted with a-
catenin and played a role in actin cytoskeleton remodeling [10]. In
myoblasts and macrophages, GEP100 was involved in cell-cell
fusion [11]. It has also been reported to take part in the regulation
of nucleolar architecture and phagocytosis [12,13]. In this study,
we did not observe any significant effect of GEP100 on cell
adhesion to collagen matrix or migration activity. Since there is
not any report on the role of GEP100 in pancreatic cancer cells,
this may be due to the difference in cell type.
Figure 1. GEP100 expression correlates closely with pancreatic cancer cell invasive ability. (A) Invasive abilities of a panel of 6 pancreatic
cancer cell lines were analyzed by Matrigel invasion assay for 24 hours. AsPc-1 and PaTu8988 showed high invasive abilities. (B) Western blot analysis
of the expression of GEP100, Arf6, E-cadherin and vimentin protein in different cell lines. AsPc-1 and PaTu8988 showed the strongest expression of
GEP100 protein, followed by SW1990, CFPAC-1, Panc-1 and BxPC-3, demonstrating a close relationship between GEP100 expression level and cell
invasive ability. No obvious relationship between the expression of Arf6 protein and invasive ability was detected. E-cadherin expression could easily
be detected in the low-invasive cell lines, but only a very weak expression was detected in the highly-invasive cell lines. Vimentin was expressed in
the highly-invasive cell lines. (C) RT-PCR analysis of the expression of GEP100, Arf6, E-cadherin and vimentin mRNA. The expression of GEP100 mRNA
could be detected in all the six cell lines and no obvious correlation with the invasive ability was found. This was the same case for Arf6 and vimentin
mRNA. E-cadherin mRNA showed a close association with the invasive ability of different cell lines. b-actin mRNA was used as a control.
doi:10.1371/journal.pone.0037854.g001
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expression and breast cancer cell invasive ability [29], we failed to
detect that in the panel of pancreatic cancer cell lines we used. The
above mentioned biological functions of GEP100 have been found
to be dependent on the activation of Arf6, but it is believed that
GEP100 is a multifunctional protein that regulates cellular
functions in both an Arf-dependent and -independent manner.
For example, GEP100 was involved in apoptotic cell death
independent of Arf6 activity [12]. Further studies including
determination of the activation status of Arf6 will be necessary
to reveal the role of Arf6 in the process of pancreatic cancer cell
invasion.
We found GEP100 knock-down caused a morphological change
of cells from mesenchymal to epithelial phenotype. In pancreatic
cancer, shifting of their epithelial features toward a mesenchymal
phenotype enhances cell motility and is considered to be
a prerequisite for tumor invasion. E-cadherin is the best
characterized molecular marker in epithelial cells and localized
at the adherens junctions. Loss of E-cadherin expression and/or
function is a well-recognized marker of EMT and promotes
invasion [18]. Therefore we examined the expression of E-
cadherin protein. GEP100 shRNAs treatment increased E-
cadherin expression level 2 to 3 -fold. This is consistent with
Hiroi’s report showing that in HepG2 cell, down-regulation of
GEP100 increased the expression of E-cadherin [10]. In addition,
they also demonstrated that GEP100 interacted with a-catenin.
E-cadherin expression could be regulated by multiple mechan-
isms including promoter methylation, transcriptional regulation by
the transcription factors including Snail, Slug, Twist, Zeb-1, Sip1,
and proper intracellular localization [30,31]. Among the tran-
scription factors we examined, the expression of slug was increased
by the down-regulation of GEP100, which was unexpected. Slug is
a member of the Snail superfamily and first identified as
a development protein critical for neural crest formation in chick
embryos [32]. Slug is inversely correlated with E-cadherin
expression and is a critical EMT-promoting factor in many tumor
types [33,34]. Recent study showed that Slug expression was not
always associated with E-cadherin down-regulation [35]. It was
Figure 2. Down-regulation of GEP100 inhibits pancreatic cancer cell invasion. (A) A stable cell line with GEP100 knocked-down was
obtained by transfecting psuper-retro-puro-GEP100 into PaTu8988 cells and selected by 1.5 mg/ml of puromycin. Down-regulation of GEP100 was
confirmed by Western blot. b-actin was used as a control. (B) Invasion assay showed that GEP100 down-regulation decreased the number of cells
penetrated through Matrigel-coated membrane. The data were presented and graphed as percentages calculated by normalizing values obtained for
the untreated cells as 100%. GEP100 knock-down decreased the number of cells penetrated through Matrigel to about 35% compared with the
control group. Re-expression of GEP100 in shRNA treated cells restored the ability of invasion to about 60%. (C, D, E) GEP100 down-regulation
showed no significant effects on cell migration, invasion and viability. Ctrl, control.
doi:10.1371/journal.pone.0037854.g002
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cancer compared with the surrounding parenchyma. However, in
the 36 cases of ductal adenocarcinoma analyzed, no obvious
relation was found between E-cadherin and Slug expression [36].
In this study we found that GEP100 down-regulation induced an
increased E-cadherin expression as well as increased Slug
expression. One interpretation is that the E-cadherin protein
expression is not dependent on Slug in this cell type and indeed the
mRNA of E-cadherin was not changed. Although the expression
of Slug is associated with many tumor prognosis, It is not clear yet
how Slug itself is regulated. Our data indicated that GEP100
might be involved in the regulation of Slug expression.
A proper localization of E-cadherin is also critical for its proper
function. Cell-surface E-cadherin in epithelial cells is partially
internalized and recycled back to the plasma membrane by
multiple mechanisms including clathrin-dependent, caveolae-de-
pendent, lipid-raft mediated pathways or macropinocytosis [31].
In epithelial junctions, the dynamics of E-cadherin was also
intimately regulated by the ARF proteins [37,38]. Arf6 GTPase is
crucial for E-cadherin endocytosis and recycling. It has been
shown that expression of an inactive Arf6T27N protein blocks
HGF-induced internalization of E-cadherin, whereas expression of
a constitutive active form of Arf6Q67L causes disassembly of
adherens junctions [39]. In HepG2 cells, GEP100 depletion
caused inactivation of Arf6 followed by impaired internalization of
E-cadherin and its accumulation at the plasmam membrane [10].
With immunofluorescence study, we found that GEP100 knock-
down increased the accumulation of E-cadherin to adherens
junctions. We speculate that GEP100 up-regulated the expression
of E-cadherin through inhibiting its endocytosis and the following
degradation. Further investigation will be necessary to clarify this
issue.
In summary, our results presented experimental evidence that
GEP100 expression correlated with the invasive ability of
Figure 3. GEP100 down-regulation inhibits liver metastasis of pancreatic cancer cells in the Balb/c nude mice with splenic injection.
(A) Macroscopic findings of the resected liver. Stable PaTu8988 cells as indicated were splenicly injected followed by spleen resection. 4 weeks later,
livers were removed for observation. Most of the livers from the control and scramble shRNA groups became small and rough, with large whitened
areas seen on the surface. For the GEP100 shRNA-injected group, only small spots were found at some of the liver surface. Metastasis was confirmed
under a microscope and the sites of metastasis were indicated by arrows (hematoxylin and eosin, x100). (B) Percentages of liver metastasis in the
Balb/c nude mice were listed. A statistically significant difference was obtained between control and experimental group (P#0.05). (C) Average
numbers of metastatic nodules in livers were calculated and graphed. Briefly, after a fixation with 10% formalin overnight, the liver was cut into 2 mm
slices and 5 sections from approximately the same positions for each liver were estimated under microscope. A statistically significant difference was
obtained between control and experimental group (P#0.05). Ctrl, control.
doi:10.1371/journal.pone.0037854.g003
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developing therapeutics to prevent pancreatic cancer cell invasion.
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